Pharmaceutics (Jun 2024)

Liposome Encapsulation Enhances the Antidiabetic Efficacy of Silibinin

  • Svetlana Dinić,
  • Jelena Arambašić Jovanović,
  • Aleksandra Uskoković,
  • Aleksandra Jovanović,
  • Nevena Grdović,
  • Jovana Rajić,
  • Marija Đorđević,
  • Ana Sarić,
  • Branko Bugarski,
  • Melita Vidaković,
  • Mirjana Mihailović

DOI
https://doi.org/10.3390/pharmaceutics16060801
Journal volume & issue
Vol. 16, no. 6
p. 801

Abstract

Read online

Silibinin has considerable therapeutic potential for the treatment of diabetes through anti-inflammatory, antioxidant, and immunomodulatory properties. However, the therapeutic application of silibinin is quite limited due to its poor bioavailability. In the present study, an attempt was made to improve the antidiabetic efficacy of silibinin by its encapsulation in liposomal vesicles. The liposomes with a high encapsulation efficiency of silibinin (96%) and a zeta potential of −26.2 ± 0.6 mV were developed and studied using nicotinamide/streptozotocin-induced diabetic rats. Administration of silibinin-loaded liposomes to diabetic rats lowered glucose levels, increased insulin levels, and improved pancreatic islet architecture. The anti-inflammatory effect of silibinin-loaded liposomes was demonstrated by a decrease in serum C-reactive protein (CRP) levels and a reduced deposition of collagen fibers in the islets of diabetic rats. Furthermore, silibinin-loaded liposomes were more efficient in lowering glucose, alanine transaminase, triglyceride, and creatinine levels in diabetic rats than pure silibinin. In addition, silibinin-loaded liposomes had a significantly better effect on beta-cell mass and Glut2 glucose receptor distribution in diabetic islets than pure silibinin. The present results clearly show that liposome encapsulation of silibinin enhances its antidiabetic efficacy, which may contribute to the therapeutic benefit of silibinin in the treatment of diabetes and its complications.

Keywords